ERBB2 and esophageal squamous cell carcinoma: Dysregulated HER2 expression has been documented in esophageal squamous cell carcinoma (ESCC; 31%) [11], metastatic breast cancer (18–20%) [7], and gastric/gastroesophageal junction cancer (15–30%) [12].